TVTX — Travere Therapeutics Inc. stock price and chart

Share this page

TVTX

$49.60-6.04%

as of close, Oct 16, 2026

☾ AH $49.60 -6.04%

Travere Therapeutics Inc.Stock · HealthcareRussell 2000 0.2%Nasdaq Composite 0.01%US Stock Market 0.007%Russell 3000 0.006%

PeersMRNALLYMDTUNHJNJTMO

Technical analysis2

Overlay lines0

Addendum charts0

VolumeEEEE

20162019202120242026

10.020.030.040.050.060.0020.0M$49.60

2026-10-16

Price$49.60

MA20$55.64

MA50$40.34

Vol10.1M

What would $1,000 invested in TVTX be worth today? →

TVTX returns: By year · By month · By week · Trailing

Key stats#

Price data

Price: $49.60
YTD price return: +29.81%
YTD total return: +29.81%
Next earnings: Oct 29, 2026
Market cap: 4.7B2016-12 714.3M2026-10 4.7B+555.1% over the window
Enterprise value: 4.6B
Shares outstanding: 94.3M2016-06 36.7M2026-06 94.3M+156.6% over the window
52W low: $22.59
52W high: $68.73
From 52W high: -27.83%
From 52W low: +119.57%
52W range: 59%

Volume

Rel volume: 1.01×
30D volume: 1.8M
30D $ vol: 105.7M

Fundamentals

Sales (ttm): 591.3M2016-12 133.6M2026-06 591.3M+342.6% over the window
Sales/share: $6.272016-12 $3.512026-06 $6.27+78.9% over the window
EPS (ttm): -$0.462016-06 $1.192026-06 -$0.46-138.6% over the window
FCF (ttm): 37.1M2015-12 -1.4M2024-09 -272.3M+19200.9% over the window
FCF/share: $0.392015-12 -$0.042024-09 -$3.49+8928.2% over the window
Book value/share: $0.262016-06 $8.562026-06 $0.26-97.0% over the window
Net margin: -7.35%2016-12 -35.9%2026-06 -7.4%-79.5% over the window
ROE: -177.24%2016-06 32.1%2026-06 -177.2%-652.1% over the window
ROA: -5.44%2016-06 18.9%2026-06 -5.4%-128.8% over the window
Current ratio: 4.052016-06 3.752026-06 4.05+7.9% over the window

Growth (CAGR, ttm) · 10Y

Sales: +77.19%2025-06-30 → 2026-06-30333.9M → 591.3M (+77.1% total)+69.91%2023-06-30 → 2026-06-30120.5M → 591.3M (+390.7% total)+23.71%2021-06-30 → 2026-06-30204.1M → 591.3M (+189.7% total)+16.96%2016-12-31 → 2026-06-30133.6M → 591.3M (+342.6% total)
Shares: +5.75%2025-06-30 → 2026-06-3089.1M → 94.3M (+5.7% total)+7.91%2023-06-30 → 2026-06-3075M → 94.3M (+25.7% total)+9.20%2021-06-30 → 2026-06-3060.7M → 94.3M (+55.2% total)+9.88%2016-06-30 → 2026-06-3036.7M → 94.3M (+156.6% total)

Per-share growth (CAGR, ttm) · 10Y

Sales/share: +67.55%2025-06-30 → 2026-06-30$3.75 → $6.27 (+67.5% total)+57.46%2023-06-30 → 2026-06-30$1.61 → $6.27 (+290.5% total)+13.29%2021-06-30 → 2026-06-30$3.36 → $6.27 (+86.6% total)+6.32%2016-12-31 → 2026-06-30$3.51 → $6.27 (+78.9% total)
Book value/share: -29.20%2025-06-30 → 2026-06-30$0.37 → $0.26 (-29.2% total)-44.87%2023-06-30 → 2026-06-30$1.55 → $0.26 (-83.2% total)-45.63%2021-06-30 → 2026-06-30$5.47 → $0.26 (-95.2% total)-29.49%2016-06-30 → 2026-06-30$8.56 → $0.26 (-97.0% total)
Price: +80.37%2025-10-16 → 2026-10-16$27.51 → $49.60 (+80.3% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+90.51%2023-10-16 → 2026-10-16$7.17 → $49.60 (+591.8% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+15.14%2021-10-15 → 2026-10-16$24.50 → $49.60 (+102.4% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+8.80%2016-10-14 → 2026-10-16$21.34 → $49.60 (+132.4% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.
Total return: +80.37%2025-10-16 → 2026-10-16$27.51 → $49.60 (+80.3% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+90.51%2023-10-16 → 2026-10-16$7.17 → $49.60 (+591.8% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+15.14%2021-10-15 → 2026-10-16$24.50 → $49.60 (+102.4% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+8.80%2016-10-14 → 2026-10-16$21.34 → $49.60 (+132.4% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)Price ÷ TTM diluted EPS. Net income carries everything below the operating line, including one-off gains. Negative when the trailing year lost money.: -107.9×2016-12 -17.102026-10 -107.66+529.5% over the window
Fwd P/E: 9.2×
P/S (ttm)Market cap ÷ TTM revenue.: 7.9×2017-03 5.272026-10 7.91+50.0% over the window
P/B (mrq)Market cap ÷ stockholders' equity at the most recent quarter end.: 190.7×2016-12 2.322026-10 190.81+8117.2% over the window
P/FCF (ttm)Market cap ÷ TTM free cash flow (operating cash flow − capex).: 126.0×2016-12 -506.222026-10 -17.18-96.6% over the window
EV/EBITDA (fy): 199.5×
EV/Sales (ttm): 7.7×
FCF yield (ttm)TTM free cash flow ÷ market cap — the inverse of P/FCF.: 0.79%2016-12 -0.7%2024-09 -24.9%+3558.8% over the window
Buyback yield (realized, 1y)1 − shares_at(2026-06-30) ÷ shares_at(2025-06-30) = 1 − 94.3M ÷ 89.1M. Point-in-time share counts from the company's own SEC filings (the same count at both ends), published only when the cash flow statement shows repurchases inside that window. A falling price can't inflate it; negative means net dilution.: -5.75%
Shareholder yield (realized, 1y)Buyback leg + dividend leg: shares retired over the year (-5.75%) + dividends paid over that year ($0) ÷ market_cap_at(2025-06-30) ($1.3B). Both legs are measured against the start of the window, so a payout can't shrink its own denominator.: -5.75%
Buyback yield (cash, ttm)Buybacks net of issuance over the trailing twelve months ($0) ÷ today's market cap ($4.7B). Dollars SPENT over what the company is worth NOW — a stock that fell after buying reads high.: 0.00%2016-09 -0.0%2026-06 0.0%-100.0% over the window
Shareholder yield (cash, ttm)(TTM buybacks net of issuance $0 + TTM dividends $0) ÷ today's market cap ($4.7B). Same caveat as the cash buyback yield.: 0.00%2016-09 -0.0%2026-06 0.0%-100.0% over the window

Vs own 10Y history

P/S: 74th
P/B: 97th

Bar = where today’s multiple sits in TVTX’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).

Performance · price return · as of 2026-10-16#

-6.04%

-4.84%

-21.87%

-10.27%

YTD

+29.81%

+80.30%

+102.45%

Financial statements

Open full TVTX financials →

Loading financial statements…

Ticker	Name	1M	1D
LLY	Eli Lilly and Company	+10.48%	+0.43%
JNJ	Johnson & Johnson	-4.38%	+0.90%
ABBV	AbbVie Inc.	+8.73%	+0.71%
UNH	UnitedHealth Group Incorporated Common Stock (DE)	+6.97%	-1.29%
MRK	Merck & Co. Inc.	+0.72%	+0.52%
NVS	Novartis AG	+8.59%	+0.16%
TMO	Thermo Fisher Scientific Inc.	+6.41%	-0.93%
AMGN	Amgen Inc.	+14.92%	-0.35%

TVTX — Travere Therapeutics Inc. price, chart and key statistics